Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland
Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb ...
Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...
BioSpace4h
BMS Wins FDA Nod for Perioperative Opdivo Regimen in NSCLC
Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...
The Pharma Letter7h
FDA approves Opdivo for lung cancer before and after surgery
Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...
The American Journal of Managed Care2h
Nivolumab Approved as Neoadjuvant, Adjuvant Therapy for NSCLC by FDA
The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
Cancer Therapy Advisor3h
Opdivo Approved in Neoadjuvant and Adjuvant Setting for Resectable NSCLC
The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.
FiercePharma21h
BMS' Opdivo joins the perioperative lung cancer treatment ring with key FDA approval
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...
pharmaphorum6h
FDA approval give BMS an edge in NSCLC treatment
In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) cleared Opdivo (nivolumab) for use with platinum-based chemo to reduce the size ...
Monthly Prescribing Reference22h
Neoadjuvant/Adjuvant Opdivo Approved for Resectable NSCLC
The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.
MedPage Today1h
Good News for CAR-T Therapy; Liquid Biopsy Progress; Anti-Psychotic for Brain Cancer
BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...
FiercePharma2h
BeiGene launches PD-1 drug Tevimbra at 10% discount to Merck's Keytruda
BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...
Medscape21h
Nivolumab NSCLC Approval Expanded to Perioperative Setting
The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...